Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 SC injection in systemic lupus erythematosus (Phase II, randomized, double-blind, placebo-controlled)
CTR20260086Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing SG301 SC injection with SG301 SC placebo (2 arms). Primary endpoint: Proportion of participants achieving SLE Responder Index-4 (SRI-4). Started Mar 2026; status: active.
02
Drugs
SG301
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20260086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260086.